Compare ASMB & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | STIM |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.1M | 120.4M |
| IPO Year | 2010 | 2018 |
| Metric | ASMB | STIM |
|---|---|---|
| Price | $25.02 | $2.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $44.20 | $3.00 |
| AVG Volume (30 Days) | 300.7K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.78 | 57.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | $638.39 | $11.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.80 | $0.80 |
| 52 Week High | $39.71 | $3.44 |
| Indicator | ASMB | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 31.19 | 54.40 |
| Support Level | $21.80 | $1.20 |
| Resistance Level | $30.26 | N/A |
| Average True Range (ATR) | 1.89 | 0.22 |
| MACD | -1.35 | -0.04 |
| Stochastic Oscillator | 3.53 | 45.16 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.